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IMPORTANCE Glyburide is thought to be safe for use during pregnancy for treatment of
gestational diabetes mellitus (GDM). However, there are limited data on the effectiveness of
glyburide when compared with insulin as used in a real-world setting.
OBJECTIVE To estimate the risk of adverse maternal and neonatal outcomes in women with
GDM treated with glyburide compared with insulin.
DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of a population-based
cohort from a nationwide US employer-based insurance claims database from January 1,
2000, to December 31, 2011. We identified women with GDM and their newborns. We
excluded those with type 1 or 2 diabetes and those younger than 15 years or older than
45 years.
EXPOSURES Treatment with glyburide or insulin during pregnancy within 150 days before
delivery.
MAIN OUTCOMES AND MEASURES We used binomial regression to estimate risk ratios (RRs)
and risk differences with 95% confidence intervals for the association of glyburide with
diagnosis codes for obstetric trauma, cesarean delivery, birth injury, preterm birth,
hypoglycemia, respiratory distress, jaundice, large for gestational age, and hospitalization in
the neonatal intensive care unit. Inverse probability of treatment weights were used to adjust
for maternal characteristics that differed between the treatment groups.
RESULTS Among 110 879 women with GDM, 9173 women (8.3%) were treated with glyburide
(n = 4982) or insulin (n = 4191). After adjusting for differences at baseline, newborns of
women treated with glyburide were at increased risk for neonatal intensive care unit
admission (RR = 1.41; 95% CI, 1.23-1.62), respiratory distress (RR = 1.63; 95% CI, 1.23-2.15),
hypoglycemia (RR = 1.40; 95% CI, 1.00-1.95), birth injury (RR = 1.35; 95% CI, 1.00-1.82), and
large for gestational age (RR = 1.43; 95% CI, 1.16-1.76) compared with those treated with
insulin; they were not at increased risk for obstetric trauma (RR = 0.92; 95% CI, 0.71-1.20),
preterm birth (RR = 1.06; 95% CI, 0.93-1.21), or jaundice (RR = 0.96; 95% CI, 0.48-1.91). The
risk of cesarean delivery was 3% lower in the glyburide group (adjusted RR = 0.97; 95% CI,
0.93-1.00). The risk difference associated with glyburide was 2.97% (95% CI, 1.82-4.12) for
neonatal intensive care unit admission, 1.41% (95% CI, 0.61-2.20) for large for gestational age,
and 1.11% (95% CI, 0.50-1.72) for respiratory distress.
CONCLUSIONS AND RELEVANCE Newborns from privately insured mothers treated with
glyburide were more likely to experience adverse outcomes than those from mothers treated
with insulin. Given the widespread use of glyburide, further investigation of these differences
in pregnancy outcomes is a public health priority.
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T he prevalence of gestational diabetes mellitus (GDM) inthe United States has more than doubled during the last20 years.1,2 Because uncontrolled hyperglycemia dur-
ing pregnancy affects fetal development and neonatal adap-
tation, adequate treatment has a direct impact on maternal and
perinatal outcomes.3 In 7% to 10% of women with GDM, rou-
tine care such as dietary measures, physical activity, and glu-
cose monitoring is not adequate to achieve glucose control.
Pharmacotherapy is indicated in this group, but evidence on
the comparative safety and effectiveness of available thera-
pies is still scarce.4
Insulin is the only pharmacological treatment approved by
the US Food and Drug Administration and endorsed by the
American Diabetes Association for the treatment of GDM in the
United States.5 Owing to its mechanism of action and ease of
use, glyburide may be an appropriate first-line treatment al-
ternative. Evidence from 3 trials suggests that, compared with
insulin, glyburide may increase the risk of neonatal jaundice,
hypoglycemia, and birth trauma,6-8 but these studies were not
powered to detect small but clinically important differences
in these and other adverse outcomes.
Given the widespread use and rapid uptake of glyburide
in the last decade, further evaluation of the comparative safety
and effectiveness of glyburide is needed.9 The purpose of this
study was to estimate the risks of adverse pregnancy out-
comes among women receiving glyburide compared with in-
sulin for the treatment of GDM in a US population-based
cohort.
Methods
We conducted a retrospective cohort study of women with
GDM identified in the Truven Health Analytics MarketScan Re-
search Databases from January 1, 2000, to December 31, 2011.
This database contains individual-level, deidentified health
care claims from employees, spouses, and dependents who are
covered by employer-sponsored private health insurance. It
is one of the largest collections of employer- and health plan–
based patient data in the United States, with approximately 30
million lives annually from January 1, 2000, to December 31,
2011, covering all US census regions.10 The database includes
inpatient and outpatient medical claims linked to outpatient
pharmacy data and person-level enrollment information. Tru-
ven Health Analytics reviews all claims and enrollment data
to ensure completeness, accuracy, and reliability. This study
was considered to be exempt from further review by the Pub-
lic Health–Nursing Institutional Review Board, Office of Hu-
man Research Ethics, University of North Carolina at Chapel
Hill. Informed consent was not required from patients be-
cause this was a retrospective study using deidentified data.
Study Population
We identified women with claims for delivery of a live-born
infant through the use of International Classification of Dis-
eases, Ninth Revision (ICD-9) diagnosis and procedure codes
as well as Current Procedural Terminology (CPT) codes (eTable
1 in the Supplement). Because multiple claims can be gener-
ated during delivery of care, we grouped those occurring con-
secutively and defined delivery date as the date of the earli-
est claim. Women were included in the cohort if they (1) had a
diagnosis code for GDM (ICD-9 codes 648.8-648.83) prior to
delivery, (2) were continuously enrolled during the year prior
to and 3 months after the delivery date, and (3) had their first
pharmacy claim for glyburide or insulin within 150 days of de-
livery. We excluded women (1) with diagnosis codes for type 1
or 2 diabetes, (2) younger than 15 years or older than 45 years,
or (3) with diagnosis or procedure codes for pregnancy with
multiple gestations. Our cohort was restricted to the first eli-
gible pregnancy with GDM for a given woman.
Linkage to Newborns
We linked women in our cohort to newborns listed under the
same policy whose first claim occurred during the same cal-
endar year as the maternal delivery date. To refine the link-
age, we required the date of the potential newborn’s first claim
to be within 30 days of the delivery date. To be considered part
of the cohort, infants had to be continuously enrolled for 3
months after the delivery date to ascertain use of health
services.
Exposure
We identified women in our cohort with a pharmacy claim for
insulin or glyburide in the 150 days prior to delivery. The in-
dex date was defined as the date for the first claim for gly-
buride or insulin before delivery. Women with a prescription
earlier than 150 days prior to delivery were excluded as use of
these medications in early pregnancy is more likely to sug-
gest prepregnancy type 2 diabetes than GDM. Classification as
an insulin or glyburide initiator was based on the drug class
of the first pharmacy claim. Duration of glyburide or insulin
treatment was defined as the number of days between the in-
dex date and delivery date, assuming that discontinuation of
treatment only occurred after birth.
Outcomes
Outcomes of interest included obstetric trauma (≥1 claim with
a diagnosis code for third- or fourth-degree perineal lacera-
tion occurring during birth), cesarean delivery, birth injury (≥1
claim with diagnosis of shoulder dystocia or fetal injury), pre-
term birth (≥1 claim with a code for birth <37 weeks’ gesta-
tion), large for gestational age (≥1 claim with a code for large
for gestational age), and admission (>24 hours) to the neona-
tal intensive care unit (NICU). For neonatal hypoglycemia, jaun-
dice, and respiratory distress, we required NICU admission
along with the diagnosis code. We defined maternal and neo-
natal outcomes through ICD-9 diagnosis, CPT, and ICD-9 pro-
cedure codes (eTable 1 in the Supplement). Outcome defini-
tions for obstetric trauma, birth injury, and preterm birth were
based on previously published validated algorithms or guide-
line recommendations.11-14
Covariates
We identified characteristics that are risk factors for the out-
comes and that influence choice of therapy (insulin or gly-
buride) for GDM. All characteristics were defined through the
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use of ICD-9 diagnosis codes, CPT codes, or pharmacy claims
and assessed before the index date (eTable 1 in the Supple-
ment). Comorbidities of interest were infertility diagnosis or
treatment (≥1 claim for clomiphene citrate, urofollitropin, fol-
litropin, menotropins, ganirelix acetate, or cetrorelix ac-
etate), obesity, hypothyroidism, hyperandrogenism, meta-
bolic syndrome, and polycystic ovarian syndrome. Because
preeclampsia and gestational hypertension could affect out-
comes and onset of GDM, we identified whether these condi-
tions occurred before the index date. Preeclampsia was de-
fined as any inpatient stay with a primary or secondary
diagnosis code for preeclampsia; gestational hypertension was
defined through the use of pharmacological treatment (earli-
est claim after index date for methyldopa, calcium channel
blockers, β-blockers, or α-blockers). Because metformin hy-
drochloride is used off label for infertility or to reduce risk of
miscarriage, we included history of metformin use as a covar-
iate in the analysis.
Statistical Analysis
Propensity score (PS)–based methods were used to control con-
founding by balancing the distribution of confounders in the
treatment groups.15 We fit a logistic regression model to esti-
mate the probability of treatment with glyburide vs insulin (or
the PS), adjusted for all covariates including age (quadratic) and
calendar year. Model fit was assessed through the Hosmer-
Lemeshow goodness-of-fit test and the PS distributions were
examined to identify areas of nonoverlap between treatment
groups. Inverse probability of treatment weights was calcu-
lated as 1/PS for those who received glyburide and 1/(1 − PS)
for those who received insulin. We assessed balance of mea-
sured confounders before and after weighting through stan-
dardized mean differences.16,17
We used binomial regression to estimate crude risk ratios
(RRs), adjusted RRs (aRRs), crude risk differences (RDs), and
adjusted RDs (aRDs). To estimate the unadjusted association,
we used a model with the exposure as the only variable. We
then applied inverse probability of treatment weights and es-
timated the adjusted risks. Robust variance was used to esti-
mate 95% confidence intervals for the association between gly-
buride vs insulin and adverse outcomes, carrying the first
exposure forward. Women were not excluded if discontinu-
ing, adding, or switching treatments, similar to an intent-to-
treat approach. Model fit was assessed using a standardized
Pearson χ2 test.
We conducted sensitivity analyses to evaluate the influ-
ence of residual confounding by maternal obesity (described
in eAppendix 1 in the Supplement; results from these analy-
ses are reported in eTables 2-4 in the Supplement). All analy-
ses were conducted using SAS version 9.3 statistical software
(SAS Institute, Inc).
Results
We identified 110 879 women with GDM and their newborns.
Of these women, 9173 (8.3%) initiated pharmacotherapy, in-
cluding 4982 (54.3%) treated with glyburide and 4191 (45.7%)
treated with insulin. Baseline characteristics of women by treat-
ment status appear in Table 1. The mean (SD) age was 33.5 (4.7)
years. The proportion of the cohort treated with glyburide in-
creased from 8.5% in 2000 to 64.4% in 2011. For both gly-
buride and insulin, women had a minimum of 1 day of treat-
ment and a maximum of 150 days, consistent with our cohort
definition. The mean (SD) duration of treatment with gly-
buride was 50.4 (27.1) days (median, 47 days), while for insu-
lin the mean (SD) was 54.1 (28.6) days (median, 50 days).
Of the 9173 women in the cohort, 451 (4.9%) added a sec-
ond medication or switched treatments after initiation. None
started both medications on the same day. Among those treated
with glyburide, 406 (8.1%) had a change from initial treat-
ment, with the majority using insulin (333 women [82.0%]).
Only 45 (1.1%) of those in the insulin group had a change from
initial treatment; the majority (31 women [68.9%]) added or
switched to glyburide.
Obesity and hospitalization for preeclampsia were more
common in the glyburide group, while hypothyroidism and in-
fertility treatment were more common in women treated with
insulin. There were no differences between groups in metfor-
min use prior to the index date (Table 1). After applying the in-
Table 1. Characteristics of Women at Initiation of Pharmacotherapy Before and After Weighting
Characteristic








(n = 4191) SMD
Age, mean (SD), y 33 (4.7) 34 (4.7) 0.04 33 (4.7) 33 (4.7) 0.00
Comorbidity, %
Infertility treatment 5.6 6.8 0.20 6.1 6.2 0.01
Hypothyroidism 7.1 8.3 0.17 7.7 7.7 0.00
PCOS 3.3 4.1 0.26 3.6 3.6 0.02
Hyperandrogenism 2.0 1.6 0.34 1.8 1.8 0.02
Metabolic syndrome 0.4 0.7 0.67 0.5 0.6 0.14
Obesity 10.0 7.3 0.33 8.8 8.8 0.00
Antihypertensive use 10.6 9.9 0.07 10.3 10.3 0.00
Metformin hydrochloride use, % 6.9 7.0 0.01 6.9 7.0 0.01
Abbreviations: PCOS, polycystic ovarian syndrome; SMD, standardized mean difference.
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verse probability of treatment weights, the 2 groups were bal-
anced in terms of baseline covariates (all standardized mean
differences <0.05) with the exception of the ICD-9 diagnosis
code for metabolic syndrome, which was present in fewer than
1% of both groups.
Table 2 shows the results of the adjusted analyses for the
risk of adverse maternal and neonatal outcomes in women ini-
tially treated with glyburide compared with those receiving in-
sulin (results of crude analysis are presented in eTable 5 in the
Supplement). Compared with insulin, we observed a higher risk
of NICU admission (aRR = 1.41; 95% CI, 1.23-1.62), respiratory
distress (aRR = 1.63; 95% CI, 1.23-2.15), neonatal hypoglyce-
mia (aRR = 1.40; 95% CI, 1.00-1.95), birth injury (aRR = 1.35; 95%
CI, 1.00-1.82), and large for gestational age (aRR = 1.43; 95% CI,
1.16-1.76) among newborns whose mothers were treated with
glyburide. Women treated with glyburide, as compared with
those treated with insulin, were not at increased risk for ob-
stetric trauma (aRR = 0.92; 95% CI, 0.71-1.20), preterm birth
(aRR = 1.06; 95% CI, 0.93-1.21), or jaundice (aRR = 0.96; 95%
CI, 0.48-1.91). The risk of cesarean delivery was 3% lower in
the glyburide group (aRR = 0.97; 95% CI, 0.93-1.00).
The RD per 100 women associated with receipt of gly-
buride vs insulin was higher for admission to the NICU
(aRD = 2.97%; 95% CI, 1.82-4.12), large for gestational age
(aRD = 1.41%; 95% CI, 0.61-2.20), and respiratory distress
(aRD = 1.11%; 95% CI, 0.50-1.72) (Table 2). The corresponding
numbers needed to treat to harm were 36 (95% CI, 25-60) for
NICU admission, 71 (95% CI, 46-164) for large for gestational
age, and 96 (95% CI, 61-233) for respiratory distress.
Discussion
In a population-based cohort of 9173 women with GDM man-
aged by pharmacotherapy, we found an association between
the use of glyburide (compared with insulin) and an in-
creased risk of adverse events. Admission to the NICU, respi-
ratory distress, and large for gestational age were more likely
to occur among women treated with glyburide. Smaller dif-
ferences between treatment groups were found for obstetric
trauma, cesarean delivery, jaundice, and preterm birth.
Previous literature on the association between treatment
with glyburide and adverse neonatal outcomes is limited. To
date, 3 trials with a total of 268 women and 3 observational
studies have assessed the safety or effectiveness of glyburide
compared with insulin in pregnancy.6-8,18-20 The trial by
Langer et al6 was by far the largest of the three (n = 201) and
was the only one to examine NICU admission, respiratory
distress, and jaundice, leading us to focus on the interpreta-
tion of our findings in the context of those by Langer et al.
While the point estimates appear to differ from those of
Langer et al in some instances (Figure), the estimates from
our study fall within the confidence limits of those by Langer
et al for all of the outcomes. Given our much larger sample,
we have been able to characterize the differences in out-
comes between women treated with glyburide vs insulin
with much greater precision.
It is also possible that differences of risk estimates be-
tween studies could be explained by differences in outcome
ascertainment. Because criteria for admission to the NICU may
be more or less conservative in a standardized protocol for the
trial compared with general practice, our results may be more
representative of practice patterns related to newborn care
across the United States. Our results for NICU admission are
also consistent with previously published work from Cheng et
al.18 Compared with the trial, our definition of respiratory dis-
tress identified critically ill infants and did not include less se-
rious diagnoses such as transient tachypnea of the newborn.
Therefore, our estimates for respiratory distress reflect more
severe conditions requiring NICU admission. The same prin-
ciple applies to jaundice and neonatal hypoglycemia where the
trials identified newborns based on predefined bilirubin or
blood glucose (for hypoglycemia) cutoff values, while our study
identified newborns with jaundice or hypoglycemia who re-
quired care in the NICU. Because large for gestational age was
defined through the use of ICD-9 codes, coding for this diag-
nosis may include both macrosomia or large for gestational age;
this could affect our estimates, underestimating the risk.
Birth injury and preterm birth were not assessed in the
clinical trials. The observational studies by Jacobson et al7 and
Ramos et al20 reported higher odds of birth injury among those
in the glyburide group (RR = 3.03; 95% CI, 0.81-11.28; and
RR = 3.55; 95% CI, 0.33-38.0, respectively), but these esti-
mates are extremely imprecise and based on few events. The
populations of these studies were largely Hispanic and in-
sured by Medicaid, whereas our study comprised individuals
Table 2. Adverse Maternal and Neonatal Outcomes
Outcome
Events, No. (%) IPTW Adjusteda
Glyburide Insulin RR (95% CI) RD, % (95% CI)
Obstetric trauma 111 (2.2) 102 (2.4) 0.92 (0.71 to 1.20) −0.19 (−0.81 to 0.43)
Cesarean delivery 2522 (50.6) 2201 (52.5) 0.97 (0.93 to 1.00) −1.79 (−3.84 to 0.26)
NICU admission 509 (10.2) 302 (7.2) 1.41 (1.23 to 1.62) 2.97 (1.82 to 4.12)
Respiratory distress 144 (2.9) 73 (1.7) 1.63 (1.23 to 2.15) 1.11 (0.50 to 1.72)
Hypoglycemia 95 (1.9) 55 (1.3) 1.40 (1.00 to 1.95) 0.55 (0.03 to 1.06)
Jaundice 17 (0.3) 15 (0.4) 0.96 (0.48 to 1.91) −0.02 (−0.26 to 0.22)
Birth injury 110 (2.2) 69 (1.6) 1.35 (1.00 to 1.82) 0.57 (0.01 to 1.14)
Preterm 472 (9.5) 371 (8.9) 1.06 (0.93 to 1.21) 0.57 (−0.62 to 1.75)
Large for
gestational age
234 (4.7) 134 (3.2) 1.43 (1.16 to 1.76) 1.41 (0.61 to 2.20)
Abbreviations: IPTW, inverse
probability of treatment weights;
NICU, neonatal intensive care unit;
RD, risk difference; RR, relative risk.
a Model adjusted using IPTW for age
and covariates of interest.
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with employer-based insurance. Even though not statisti-
cally significant in our study, the risk of birth injury is consis-
tent with previously reported results and should be consid-
ered (Figure). Compared with the clinical trials and
observational studies, our study population makes our find-
ings more precise and potentially more generalizable than those
of previous studies.
Limitations of our study include absence of information
on gestational age, no ascertainment of stillbirths, lack of in-
formation on race/ethnicity and sociodemographic vari-
ables, and the potential for unmeasured confounding. Al-
though we were unable to identify the precise beginning of
pregnancy, by using a validated approach and only including
those treated within 150 days of delivery we believe our co-
hort is reflective of patients with true GDM.21 Owing to ab-
sence of linkage with death certificate data, we were unable
to adequately ascertain stillbirths or neonatal deaths. Previ-
ous studies have shown heterogeneity in the risk of adverse
neonatal events by race or sociodemographic status. How-
ever, there is no evidence of differences by race after women
initiate pharmacological treatment, and the role of these fac-
tors in the selection of pharmacological treatment has not been
determined. We do not have data on the severity of glucose
intolerance for the population, although analysis of a sub-
group with laboratory results found no indication that base-
line levels of glucose intolerance differed between the groups
(eAppendix 2, eTable 6, and eTable 7 in the Supplement). Be-
cause this population represents those with employer-based
insurance, results from this study may not be generalizable to
uninsured individuals or those covered by Medicaid.
Residual confounding due to differences in obesity be-
tween the groups is also a potential concern. Previous studies
have shown that use of ICD-9 codes for obesity has a high posi-
tive predictive value (93%) but low sensitivity.21 Thus, our defi-
nition of obesity is more likely to capture morbidly obese
women. We assessed whether the effect of obesity on out-
comes could be differential between treatment groups. Our sec-
ondary analysis shows that the effect of obesity on outcomes
is consistent with that reported in previous studies and in the
same direction for both treatment groups.22-24 In a previous
analysis, we observed that obesity was not associated with the
choice of treatment.9 Therefore, although obesity is likely
underreported in our cohort, this is not sufficient to explain
the observed differences between the treatment groups
(eAppendix 1 and eTables 2-4 in the Supplement).
To our knowledge, this is the largest US population-
based study to date to assess the comparative effectiveness of
glyburide in pregnancy. Patterns observed in our data set re-
flect usual care among the employed and insured population
in the United States, whereas clinical trials include a highly se-
Figure. Comparison Between Estimates of Relative Risk and 95% Confidence Intervals From Randomized
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lected patient population treated under standard protocols and
consistent monitoring. When compared with self-report, as-
certainment of initiation of treatment through pharmacy claims
is substantially improved; however, we are unable to ascer-
tain initial dosage and dosage escalation, which affect glu-
cose control. Because serious maternal and neonatal out-
comes are relatively rare, large claims databases provide a
unique opportunity to study the safety and effectiveness of
medications in pregnancy.
A higher risk of neonatal outcomes associated with gly-
buride-treated women demands further attention. Preven-
tion of neonatal outcomes has short-term effects in terms of
morbidity and costs of care. In addition, recent studies have
suggested a link between metabolic disturbances in the neo-
natal period and the risk of insulin resistance or obesity in child-
hood or adulthood.25,26 Clinically, this implies that better man-
agement of women treated with glyburide is needed. Evidence-
based recommendations are needed to provide guidance
regarding dosing and to identify women more likely to ben-
efit from glyburide.
Conclusions
After accounting for maternal comorbidities and risk factors
for neonatal outcomes, we found an association between gly-
buride (compared with insulin) and elevated risk of NICU ad-
mission, neonatal hypoglycemia, respiratory distress, birth in-
jury, and large for gestational age in women with GDM. These
results are consistent with findings from prior studies and sug-
gest that women with GDM being treated with glyburide may
not be achieving adequate glucose control.
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